{"filter":{"intervention":"live_biotherapeutic"},"n_projects":13,"projects":[{"accession":"PRJNA1121316","age_categories":{"unknown":500},"countries":{"CA":204,"US":296},"first_public_year":"2024","gbp_per_sample_median":0.58,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"gi_infection_or_diarrhoea":500},"intervention_design":"randomized_controlled_trial","intervention_detail":"VE303, defined 8-strain bacterial consortium, oral, 14 days","interventions":["live_biotherapeutic"],"n_samples":500,"papers":[{"doi":"10.1001/jama.2023.4314","pmcid":"PMC10105904","pmid":"37060545","title":"VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial."},{"doi":"10.1038/s41591-024-03337-4","pmcid":null,"pmid":"39747680","title":"Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection."}],"sample_intervention_arms":{},"sex":{},"title":"CONSORTIUM VE303 phase 2 study stool metagenomes","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1121316","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1121316_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1121316.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1121316.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1121316.csv.gz"}},{"accession":"PRJNA755324","age_categories":{"adult":450},"countries":{"US":450},"first_public_year":"2022","gbp_per_sample_median":6.32,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"randomized_controlled_trial","intervention_detail":"VE303 (8-strain LBP) dosed after vancomycin pretreatment, phase 1a/b","interventions":["antibiotic","live_biotherapeutic"],"n_samples":450,"papers":[{"doi":"10.1016/j.chom.2022.03.016","pmcid":null,"pmid":"35421353","title":"Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers."},{"doi":"10.3390/pharmaceutics17121603","pmcid":"PMC12736906","pmid":"41471117","title":"<i>Flavonifractor plautii</i> as a Next-Generation Probiotic Enhancing the NGP F/P Index in a Simulated Human Gut Microbiome Ecosystem."},{"doi":"10.1371/journal.pbio.3003638","pmcid":"PMC12919772","pmid":"41712536","title":"Metabolic modeling reveals determinants of prebiotic and probiotic treatment efficacy across multiple human intervention trials."}],"sample_intervention_arms":{"no_intervention":64},"sex":{},"title":"Colonization of the Live Biotherapeutic Product VE303 and Modulation of the Microbiota and Metabolites in Healthy Volunteers","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA755324","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA755324_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA755324.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA755324.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA755324.csv.gz"}},{"accession":"PRJNA1463324","age_categories":{"adult":273},"countries":{"BE":273},"first_public_year":"2026","gbp_per_sample_median":1.37,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"healthy_control":273},"intervention_design":"randomized_controlled_trial","intervention_detail":"Oral vancomycin pretreatment then VE202 16-strain bacterial consortium, single/multiple dose","interventions":["antibiotic","live_biotherapeutic"],"n_samples":273,"papers":[{"doi":"10.1097/meg.0000000000003098","pmcid":null,"pmid":"41342324","title":"A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dy"}],"sample_intervention_arms":{"live_biotherapeutic":174,"no_intervention":70,"placebo":29},"sex":{},"title":"VE202 phase 1 stool metagenomes","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1463324","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1463324_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1463324.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1463324.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1463324.csv.gz"}},{"accession":"PRJNA1224809","age_categories":{"unknown":207},"countries":{"US":207},"first_public_year":"2025","gbp_per_sample_median":16.53,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"kidney_disease":207},"intervention_design":"single_arm_before_after","intervention_detail":"NOV-001: recombinant live biotherapeutic NB1000S plus polysaccharide NB2000P","interventions":["live_biotherapeutic","prebiotic_or_fibre"],"n_samples":207,"papers":[{"doi":"10.1126/science.adu8000","pmcid":"PMC13308544","pmid":"40674481","title":"Controlled colonization of the human gut with a genetically engineered microbial therapeutic."}],"sample_intervention_arms":{},"sex":{},"title":"Novome metagenomic data","trial_population_condition":"kidney_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1224809","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1224809_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1224809.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1224809.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1224809.csv.gz"}},{"accession":"PRJNA1364832","age_categories":{"adult":129},"countries":{"NL":129},"first_public_year":"2026","gbp_per_sample_median":5.1,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"healthy_control":129},"intervention_design":"randomized_controlled_trial","intervention_detail":"Vancomycin pretreatment then NTCD spore capsules vs placebo","interventions":["antibiotic","live_biotherapeutic"],"n_samples":129,"papers":[{"doi":"10.1038/s41467-026-74327-y","pmcid":"PMC13408661","pmid":"42286003","title":"Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial."}],"sample_intervention_arms":{"live_biotherapeutic":1,"placebo":16},"sex":{},"title":"Gut microbiome profiles following vancomycin pretreatment in an experimental human C. difficile colonisation model","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1364832","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1364832_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1364832.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1364832.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1364832.csv.gz"}},{"accession":"PRJNA978931","age_categories":{"adult":101},"countries":{"US":101},"first_public_year":"2024","gbp_per_sample_median":21.61,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":101},"intervention_design":"randomized_controlled_trial","intervention_detail":"SER-401 spore formulation + vancomycin preconditioning + nivolumab vs placebo, melanoma","interventions":["antibiotic","drug_therapy","live_biotherapeutic"],"n_samples":101,"papers":[{"doi":"10.1158/2159-8290.cd-24-0066","pmcid":"PMC11215408","pmid":"38588588","title":"Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity."}],"sample_intervention_arms":{},"sex":{},"title":"Microbiome intervention with SER-401 prior to nivolumab for unresectable or metastatic melanoma: a randomized placebo-controlled, biomarker-stratified multicenter phase 1b trial","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA978931","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA978931_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA978931.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA978931.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA978931.csv.gz"}},{"accession":"PRJNA1322507","age_categories":{"adult":87},"countries":{"US":87},"first_public_year":"2026","gbp_per_sample_median":8.69,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"gi_infection_or_diarrhoea":87},"intervention_design":"randomized_controlled_trial","intervention_detail":"15-strain LBP (MTC01) vs same-donor FMT, low/high dose","interventions":["fmt","live_biotherapeutic"],"n_samples":87,"papers":[{"doi":"10.1038/s41591-026-04442-2","pmcid":"PMC13444918","pmid":"42230754","title":"15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial."}],"sample_intervention_arms":{},"sex":{},"title":"Live biotherapeutic product MTC01 vs FMT","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1322507","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1322507_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1322507.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1322507.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1322507.csv.gz"}},{"accession":"PRJEB62463","age_categories":{"unknown":86},"countries":{"SE":86},"first_public_year":"2023","gbp_per_sample_median":13.48,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{},"intervention_design":"single_arm_before_after","intervention_detail":"Oxygen-tolerant F. prausnitzii + D. piger synbiotic formulation (NCT03728868)","interventions":["live_biotherapeutic"],"n_samples":86,"papers":[{"doi":"10.1038/s41586-023-06378-w","pmcid":"PMC10412450","pmid":"37532933","title":"Synergy and oxygen adaptation for development of next-generation probiotics."}],"sample_intervention_arms":{},"sex":{},"title":"Synergy and oxygen adaptation for development of next generation probiotics","trial_population_condition":"healthy_control","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB62463","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB62463_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB62463.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB62463.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB62463.csv.gz"}},{"accession":"PRJNA1062109","age_categories":{"adult":73},"countries":{"FR":73},"first_public_year":"2025","gbp_per_sample_median":10.99,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"other_cancer":73},"intervention_design":"single_arm_before_after","intervention_detail":"MaaT033 pooled fecal microbiotherapy capsules after chemotherapy, phase 1b","interventions":["live_biotherapeutic"],"n_samples":73,"papers":[{"doi":"10.1182/bloodadvances.2024015571","pmcid":"PMC12305571","pmid":"40197991","title":"Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial."}],"sample_intervention_arms":{},"sex":{},"title":"Safety and Tolerability Evaluation of MaaT033 (CIMON)","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1062109","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1062109_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1062109.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1062109.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1062109.csv.gz"}},{"accession":"PRJEB56674","age_categories":{"adult":72},"countries":{"CA":72},"first_public_year":"2023","gbp_per_sample_median":4.22,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"gi_infection_or_diarrhoea":72},"intervention_design":"non_randomized_controlled","intervention_detail":"Microbial consortium (MET-2) vs FMT for recurrent C. difficile infection","interventions":["fmt","live_biotherapeutic"],"n_samples":72,"papers":[{"doi":"10.1128/mbio.03482-22","pmcid":"PMC10506460","pmid":"37404011","title":"A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection."}],"sample_intervention_arms":{"fmt":14,"live_biotherapeutic":38,"no_intervention":20},"sex":{},"title":"Proteobacteria and antimicrobial resistant genes after microbial consortia","trial_population_condition":"gi_infection_or_diarrhoea","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB56674","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB56674_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB56674.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB56674.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB56674.csv.gz"}},{"accession":"PRJEB110888","age_categories":{"adult":63},"countries":{},"first_public_year":"2026","gbp_per_sample_median":5.82,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":false,"health_conditions":{"crohns_disease":63},"intervention_design":"single_arm_before_after","intervention_detail":"Oral F. prausnitzii strain EXL01, single-arm, open-label","interventions":["live_biotherapeutic"],"n_samples":63,"papers":[{"doi":"10.1038/s41467-026-72375-y","pmcid":"PMC13332046","pmid":"42049742","title":"Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn's Disease: a first in human trial."}],"sample_intervention_arms":{},"sex":{},"title":"Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn’s Disease: a first in human trial","trial_population_condition":"crohns_disease","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJEB110888","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB110888_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJEB110888.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJEB110888.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJEB110888.csv.gz"}},{"accession":"PRJNA1219628","age_categories":{"adult":46},"countries":{"CA":46},"first_public_year":"2025","gbp_per_sample_median":0.13,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"other_cancer":46},"intervention_design":"single_arm_before_after","intervention_detail":"MET4 bacterial consortium given to immune checkpoint inhibitor recipients","interventions":["live_biotherapeutic"],"n_samples":46,"papers":[{"doi":"10.1136/jitc-2024-010681","pmcid":"PMC11979602","pmid":"40121033","title":"Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors."},{"doi":"10.1128/mbio.01904-25","pmcid":"PMC12607873","pmid":"40996271","title":"Assessment of ecological fidelity of human microbiome-associated mice in observational studies and an interventional trial."}],"sample_intervention_arms":{"live_biotherapeutic":23,"no_intervention":23},"sex":{},"title":"MET4 recipient stools","trial_population_condition":"other_cancer","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA1219628","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1219628_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA1219628.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA1219628.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA1219628.csv.gz"}},{"accession":"PRJNA754443","age_categories":{"unknown":12},"countries":{"US":12},"first_public_year":"2021","gbp_per_sample_median":15.29,"has_cases_and_healthy_controls":false,"has_treated_and_control_arms":true,"health_conditions":{"intervention_cohort":12},"intervention_design":"unknown","intervention_detail":"Phase 1b trial of a novel live biotherapeutic product; active ingredient strain tracked in treated participants","interventions":["live_biotherapeutic"],"n_samples":12,"papers":[{"doi":"10.1099/mgen.0.000794","pmcid":"PMC9176275","pmid":"35302439","title":"Finding the right fit: evaluation of short-read and long-read sequencing approaches to maximize the utility of clinical microbiome data."},{"doi":"10.1101/2021.08.31.458285","pmcid":null,"pmid":null,"title":"Finding the right fit: A comprehensive evaluation of short-read and long-read sequencing approaches to maximize the utility of clinical microbiome data"},{"doi":"10.1186/s12859-024-05634-8","pmcid":"PMC10782538","pmid":"38212694","title":"Comparative analysis of metagenomic classifiers for long-read sequencing datasets."}],"sample_intervention_arms":{"live_biotherapeutic":6,"no_intervention":6},"sex":{},"title":"Comparison of short-read and long-read amplicon and metagenomic sequencing data from clinical microbiome samples","trial_population_condition":"unknown","urls":{"ena":"https://www.ebi.ac.uk/ena/browser/view/PRJNA754443","evidence_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA754443_determinations.csv.gz","page":"https://olmlab.github.io/microbiome_repo/studies/PRJNA754443.html","samples_csv":"https://olmlab.github.io/microbiome_repo/api/samples/PRJNA754443.csv","samples_full_csv_gz":"https://olmlab.github.io/microbiome_repo/data/studies/PRJNA754443.csv.gz"}}],"release":"R2026.25"}